Related Experiment Video
Updated: Jun 25, 2026
12:42
Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Telomerase-specific virotherapy for human squamous cell carcinoma
1Okayama University Hospital, Center for Gene and Cell Therapy, 2-5-1 Shikata-cho, Okayama 700-8558, Japan. toshi_f@md.okayama-u.ac.jp
Expert Opinion on Biological Therapy
|February 17, 2009
Summary
Telomerase-specific oncolytic viruses were developed to target cancer by replicating within tumors. These viruses efficiently killed human squamous cell carcinoma cells, showing potential for head and neck cancer treatment.
Area of Science:
- Oncolytic virotherapy
- Cancer biology
- Molecular oncology
Background:
- Replication-selective, tumor-specific viruses offer a novel cancer treatment strategy.
- Human telomerase reverse transcriptase (hTERT) is highly expressed in over 85% of cancers.
- hTERT promoter activity can confer tumor specificity to viral replication.
Purpose of the Study:
- To develop and evaluate oncolytic viruses (Telomelysin and TelomeScan) utilizing hTERT promoter specificity.
- To confirm the efficacy of these viruses against human squamous cell carcinoma.
Main Methods:
- Development of oncolytic viruses with hTERT promoter-driven replication.
- In vitro and in vivo testing of viral efficacy on human cancer cell lines, including SCCHN.
- Assessment of viral replication and tumor cell lysis.
Main Results:
- The developed oncolytic viruses demonstrated efficient replication in cancer cells.
- Significant tumor cell killing was observed in vitro and in vivo.
- Viruses showed efficacy against human squamous cell carcinoma (SCCHN) cell lines.
Conclusions:
- Telomerase-specific oncolytic viruses are effective against human squamous cell carcinoma.
- These viruses exhibit efficient replication and tumor cell lysis.
- Intratumoral virotherapy using telomerase-specific oncolytic viruses holds promise for SCCHN treatment.
Related Concept Videos
02:41Telomeres and Telomerase
In eukaryotic DNA replication, a single-stranded DNA fragment remains at the end of a chromosome after the removal of the final primer. This section of DNA cannot be replicated in the same manner as the rest of the strand because there is no 3’ end to which the newly synthesized DNA can attach. This non-replicated fragment results in gradual loss of the chromosomal DNA during each cell duplication. Additionally, it can induce a DNA damage response by enzymes that recognize single-stranded DNA.
02:41Telomeres and Telomerase
In eukaryotic DNA replication, a single-stranded DNA fragment remains at the end of a chromosome after the removal of the final primer. This section of DNA cannot be replicated in the same manner as the rest of the strand because there is no 3’ end to which the newly synthesized DNA can attach. This non-replicated fragment results in gradual loss of the chromosomal DNA during each cell duplication. Additionally, it can induce a DNA damage response by enzymes that recognize single-stranded DNA.
02:15Replicative Cell Senescence
Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:22Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
01:51Mechanisms of Retrovirus-induced Cancers
Retroviruses are RNA viruses that have been shown to cause cancers in diverse species, including chickens, mice, cats, and monkeys. The RNA genomes of these viruses are first reverse-transcribed into single and then double-stranded DNA (dsDNA) copies. This dsDNA called proviral DNA then integrates into the host genome. Subsequently, the host cell transcribes the proviral DNA in concert with the chromosomal DNA. This leads to the production of viral RNA and proteins that assemble at the host...